AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia.
Srividya B BalachanderSteven W CriscioneKate F BythJustin CidadoAmmar AdamPaula LewisTerry MacintyreShenghua WenDeborah LawsonKathleen BurkeTristan LubinskiJeffrey W TynerStephen E KurtzShannon K McWeeneyJeffrey VarnesR Bruce DieboldThomas GeroStephanos IoannidisEdward J HennessyWilliam McCoullJamal C SaehAreya TabatabaiOmid TavanaNancy SuAlwin SchullerMathew J GarnettPatricia JaaksElizabeth A CokerGareth Peter GregoryAndrea NewboldRicky W JohnstoneEric GanglMartin WildMichael ZindaJ Paul SecristBarry R DaviesStephen E FawellFrancis D GibbonsPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
AZD4320 is a potent molecule with manageable thrombocytopenia risk to explore the utility of a dual Bcl-2/Bcl-xL inhibitor across a broad range of tumor types with dysregulation of Bcl-2 prosurvival proteins.